Area of research
Immunology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Immune Cell Function and Interaction, Immunotherapy and Immune Responses, T-cell and B-cell Immunology, and Monoclonal and Polyclonal Antibodies Research.
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer
Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site
HLA-E[pHLA-G] complex–specific monoclonal antibody enhancing NK activity in multiple myeloma
optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material
Hepatitis B Virus Neutralization with DNA Origami Nanoshells
Multimodal HLA-I genotype regulation by human cytomegalovirus US10 and resulting surface patterning
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
Diverse cytomegalovirus US11 antagonism and MHC-A evasion strategies reveal a tit-for-tat coevolutionary arms race in hominids
Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies
Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells
Multimodal HLA-I genotype regulation by human cytomegalovirus US10 and resulting surface patterning
<scp>NKG2A</scp>‐checkpoint inhibition and its blockade critically depends on peptides presented by its ligand <scp>HLA‐E</scp>
<scp>NKG2A</scp>‐checkpoint inhibition and its blockade critically depends on peptides presented by its ligand <scp>HLA‐E</scp>
NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins
Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models
T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice
Hepatitis B virus envelope proteins can serve as therapeutic targets embedded in the host cell plasma membrane
Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein
Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy
MLLT6 maintains PD‐L1 expression and mediates tumor immune resistance
Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self
Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy
Hepatitis B virus envelope proteins can serve as therapeutic targets embedded in the host cell plasma membrane
Activating NK- receptors, homing selectins and inhibitory Siglecs recognize EBOLA-GP and HPV-L1NK
HLA-B locus products resist degradation by the human cytomegalovirus immunoevasin US11
Abstract A069: NIM15 blockade – A new stroma-targeting approach for the treatment of epithelial ovarian cancer
Distinct HLA-E Peptide Complexes Modify Antibody-Driven Effector Functions of Adaptive NK Cells
HLA-E Peptide Repertoire and Dimorphism—Centerpieces in the Adaptive NK Cell Puzzle?
Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses